公司资料
Evogene 股价、新闻与催化剂
- 股票代码:
- EVGN
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- Israel
股票表现
0.44 USD (+9.70%)
收盘价
最后更新: 2026年10月1日
6.14M USD
市值
股价为何变动
截至 2026年10月1日，EVGN 上涨 9.70%，收于 $0.4356。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
Evogene is a computational biology and platform company focused on using data science to design biological products across agriculture and life sciences. Its business is more about biological engineering than drug development.
所在地与行业分类
Evogene is headquartered in Israel and listed on NASDAQ. It sits in biotechnology tools and computational biology.
商业模式特征
The company depends on platform adoption, strategic partnerships, and the ability to monetize computational biology across multiple end markets. Investors watch collaborations, platform breadth, and commercial execution.
生物医药行业定位
Evogene occupies a platform-biology niche rather than a classic therapeutics role. It matters to the broader biotech ecosystem because it enables biological design and discovery.
未来催化剂
- Evogene’s catalysts are platform execution across ag-biotech and pharma discovery, plus any update that shows its computational biology approach can keep producing value. The market will watch whether the platform remains relevant.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。